{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T00:16:48Z","timestamp":1789172208157,"version":"build-2803163510"},"reference-count":49,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:00:00Z","timestamp":1787011200000},"content-version":"vor","delay-in-days":229,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 NS113854"],"award-info":[{"award-number":["R01 NS113854"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Children\u2019s Tumor Foundation Young Investigator Award","award":["CTF-2023-01-008"],"award-info":[{"award-number":["CTF-2023-01-008"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Neurofibromatosis type 2 (NF2)-associated meningiomas and schwannomas are vascular tumors, and while vascular endothelial growth factor (VEGF) inhibition with bevacizumab has benefited some NF2-related schwannomas, most NF2-associated meningiomas remain nonresponsive.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Leveraging our transcriptomic data, we performed Gene Ontology (GO) analysis comparing NF2-deficient meningioma cells with NF2-expressing arachnoid cells (ACs). We then established a 3D in vitro angiogenesis model by co-culturing NF2-null meningioma cells with human umbilical vein endothelial cells (HUVECs). Endothelial sprouting was assessed by CD31\/PECAM immunostaining. Effects of third-generation mechanistic target of rapamycin complex 1 (mTORC1)-selective inhibitor RMC-6272 as well as APLN knock-out using CRISPR-Cas9 gene editing were also examined.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>GO analysis identified vascular development among the top significantly upregulated pathways in NF2-deficient cells. In 3D co-culture, ECs formed radially sprouting tube-like networks from the spheroid surface, and our data supports an angiogenesis phenotype driven by meningioma cells. Given these results along with hyperactivation of mTORC1 upon NF2-deficiency, we examined whether RMC-6272 disrupts meningioma-driven angiogenesis. RMC-6272 potently suppressed EC sprouting. Cross-referencing baseline transcriptomic data, we identified Apelin (APLN), the ligand for APLN receptor (APLNR), as a basally upregulated angiogenic factor in NF2-deficient meningiomas. Quantitative RT-PCR (qRT-PCR) confirmed increased APLN expression in NF2-null immortalized and patient-derived meningioma lines, with reduced expression upon mTORC1 inhibition. Apelin-13 stimulation enhanced sprouting, whereas APLN deletion reduced endothelial sprouting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Here we establish a 3D-tumoroid model and implicate tumor-derived Apelin as an important contributor to NF2-associated meningioma angiogenesis. Our data also suggest that APLN expression is regulated, at least in part, by mTORC1. Together, these results provide a preclinical platform for investigating angiogenic vulnerabilities beyond VEGF in NF2-deficient meningiomas.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/noajnl\/vdag218","type":"journal-article","created":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T12:50:48Z","timestamp":1786798248000},"source":"Crossref","is-referenced-by-count":0,"title":["A 3D\n                    <i>in vitro<\/i>\n                    co-culture model to investigate tumor-endothelial interactions in Neurofibromatosis type 2-associated meningiomas"],"prefix":"10.1093","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9760-290X","authenticated-orcid":false,"given":"Srirupa","family":"Bhattacharyya","sequence":"first","affiliation":[{"name":"Department of Neurology, Center for Genomic Medicine, Massachusetts General Hospital , Boston, Massachusetts,","place":["USA"]},{"name":"Harvard Medical School , Boston, Massachusetts,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta L","family":"Beauchamp","sequence":"additional","affiliation":[{"name":"Department of Neurology, Center for Genomic Medicine, Massachusetts General Hospital , Boston, Massachusetts,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4966-5268","authenticated-orcid":false,"given":"Vijaya","family":"Ramesh","sequence":"additional","affiliation":[{"name":"Department of Neurology, Center for Genomic Medicine, Massachusetts General Hospital , Boston, Massachusetts,","place":["USA"]},{"name":"Harvard Medical School , Boston, Massachusetts,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,8,17]]},"reference":[{"key":"2026091119565791400_vdag218-B1","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1002\/humu.20317","article-title":"The distribution of constitutional and somatic mutations in the neurofibromatosis 2 gene","volume":"27","author":"Baser","year":"2006","journal-title":"Hum Mutat"},{"key":"2026091119565791400_vdag218-B2","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1007\/s00401-019-02029-5","article-title":"An update on the CNS manifestations of neurofibromatosis type 2","volume":"139","author":"Coy","year":"2020","journal-title":"Acta Neuropathol"},{"key":"2026091119565791400_vdag218-B3","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1136\/jmg.2010.085241","article-title":"Cranial meningiomas in 411 neurofibromatosis type 2 (NF2) patients with proven gene mutations: clear positional effect of mutations, but absence of female severity effect on age at onset","volume":"48","author":"Smith","year":"2011","journal-title":"J Med Genet"},{"key":"2026091119565791400_vdag218-B4","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1086\/342716","article-title":"Predictors of the risk of mortality in neurofibromatosis 2","volume":"71","author":"Baser","year":"2002","journal-title":"Am J Hum Genet"},{"key":"2026091119565791400_vdag218-B5","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.2217\/fon-2018-0006","article-title":"An overview of meningiomas","volume":"14","author":"Buerki","year":"2018","journal-title":"Future Oncol"},{"key":"2026091119565791400_vdag218-B6","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.cancergencyto.2005.04.003","article-title":"Inactivation patterns of NF2 and DAL-1\/4.1B (EPB41L3) in sporadic meningioma","volume":"162","author":"Nunes","year":"2005","journal-title":"Cancer Genet Cytogenet"},{"key":"2026091119565791400_vdag218-B7","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1038\/ng0294-180","article-title":"Evidence for the complete inactivation of the NF2 gene in the majority of sporadic meningiomas","volume":"6","author":"Ruttledge","year":"1994","journal-title":"Nat Genet"},{"key":"2026091119565791400_vdag218-B8","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1007\/s11060-023-04259-w","article-title":"Preoperative meningioma vascularity index is associated with significantly increased intraoperative blood loss and greater risk of subtotal resection","volume":"161","author":"Ghodrati","year":"2023","journal-title":"J Neurooncol"},{"key":"2026091119565791400_vdag218-B9","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1056\/NEJMoa0902579","article-title":"Hearing improvement after bevacizumab in patients with neurofibromatosis type 2","volume":"361","author":"Plotkin","year":"2009","journal-title":"N Engl J Med"},{"key":"2026091119565791400_vdag218-B10","doi-asserted-by":"publisher","first-page":"e59941","DOI":"10.1371\/journal.pone.0059941","article-title":"Bevacizumab treatment for meningiomas in NF2: a retrospective analysis of 15 patients","volume":"8","author":"Nunes","year":"2013","journal-title":"PLoS One"},{"key":"2026091119565791400_vdag218-B11","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1007\/s11060-025-05020-1","article-title":"Effect of bevacizumab on non-target intracranial meningiomas and non-vestibular schwannomas in NF2-related schwannomatosis: NF104","volume":"173","author":"Nakhate","year":"2025","journal-title":"J Neurooncol"},{"key":"2026091119565791400_vdag218-B12","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1002\/gcc.10282","article-title":"NF2: the wizardry of merlin","volume":"38","author":"Xiao","year":"2003","journal-title":"Genes Chromosomes Cancer"},{"key":"2026091119565791400_vdag218-B13","doi-asserted-by":"publisher","first-page":"4250","DOI":"10.1128\/MCB.01581-08","article-title":"NF2\/merlin is a novel negative regulator of mTOR complex 1, and activation of mTORC1 is associated with meningioma and schwannoma growth","volume":"29","author":"James","year":"2009","journal-title":"Mol Cell Biol"},{"key":"2026091119565791400_vdag218-B14","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1038\/onc.2014.164","article-title":"mTORC1 drives HIF-1alpha and VEGF-A signalling via multiple mechanisms involving 4E-BP1, S6K1 and STAT3","volume":"34","author":"Dodd","year":"2015","journal-title":"Oncogene"},{"key":"2026091119565791400_vdag218-B15","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1158\/1535-7163.MCT-21-0143","article-title":"Phase 0 clinical trial of everolimus in patients with vestibular schwannoma or meningioma","volume":"20","author":"Karajannis","year":"2021","journal-title":"Mol Cancer Ther"},{"key":"2026091119565791400_vdag218-B16","doi-asserted-by":"publisher","first-page":"17414","DOI":"10.1073\/pnas.0809136105","article-title":"Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation","volume":"105","author":"Choo","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026091119565791400_vdag218-B17","doi-asserted-by":"publisher","first-page":"vdae024","DOI":"10.1093\/noajnl\/vdae024","article-title":"Preclinical evaluation of the third-generation, bi-steric mechanistic target of rapamycin complex 1-selective inhibitor RMC-6272 in NF2-deficient models","volume":"6","author":"Bhattacharyya","year":"2024","journal-title":"Neurooncol Adv"},{"key":"2026091119565791400_vdag218-B18","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1093\/neuonc\/not242","article-title":"mTORC1 inhibition delays growth of neurofibromatosis type 2 schwannoma","volume":"16","author":"Giovannini","year":"2014","journal-title":"Neuro Oncol"},{"key":"2026091119565791400_vdag218-B19","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1089\/ten.TEC.2012.0684","article-title":"In vitro angiogenesis induced by tumor-endothelial cell co-culture in bilayered, collagen I hydrogel bioengineered tumors","volume":"19","author":"Szot","year":"2013","journal-title":"Tissue Eng Part C Methods"},{"key":"2026091119565791400_vdag218-B20","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1242\/jcs.00281","article-title":"Tumour-endothelium interactions in co-culture: coordinated changes of gene expression profiles and phenotypic properties of endothelial cells","volume":"116","author":"Khodarev","year":"2003","journal-title":"J Cell Sci"},{"key":"2026091119565791400_vdag218-B21","doi-asserted-by":"publisher","first-page":"5293","DOI":"10.7150\/ijbs.96469","article-title":"Three-dimensional in vitro cell cultures as a feasible and promising alternative to two-dimensional and animal models in cancer research","volume":"20","author":"Esposito","year":"2024","journal-title":"Int J Biol Sci"},{"key":"2026091119565791400_vdag218-B22","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19010181","article-title":"Halfway between 2D and animal models: are 3D cultures the ideal tool to study cancer-microenvironment interactions?","volume":"19","author":"Hoarau-Vechot","year":"2018","journal-title":"Int J Mol Sci"},{"key":"2026091119565791400_vdag218-B23","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1038\/labinvest.3700307","article-title":"Establishment of a benign meningioma cell line by hTERT-mediated immortalization","volume":"85","author":"Puttmann","year":"2005","journal-title":"Lab Invest"},{"key":"2026091119565791400_vdag218-B24","doi-asserted-by":"publisher","first-page":"100157","DOI":"10.1074\/jbc.RA120.014960","article-title":"mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition","volume":"296","author":"Beauchamp","year":"2021","journal-title":"J Biol Chem"},{"key":"2026091119565791400_vdag218-B25","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.1002\/1097-0142(19891201)64:11&lt;2243::AID-CNCR2820641110&gt;3.0.CO;2-S","article-title":"Establishment of a human malignant meningioma cell line with amplified c-myc oncogene","volume":"64","author":"Tanaka","year":"1989","journal-title":"Cancer"},{"key":"2026091119565791400_vdag218-B26","doi-asserted-by":"publisher","first-page":"16981","DOI":"10.18632\/oncotarget.4858","article-title":"A high-throughput kinome screen reveals serum\/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas","volume":"6","author":"Beauchamp","year":"2015","journal-title":"Oncotarget"},{"key":"2026091119565791400_vdag218-B27","doi-asserted-by":"publisher","first-page":"e0197350","DOI":"10.1371\/journal.pone.0197350","article-title":"Traditional and systems biology based drug discovery for the rare tumor syndrome neurofibromatosis type 2","volume":"13","author":"Synodos For","year":"2018","journal-title":"PLoS One"},{"key":"2026091119565791400_vdag218-B28","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/1471-2105-14-128","article-title":"Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool","volume":"14","author":"Chen","year":"2013","journal-title":"BMC Bioinformatics"},{"key":"2026091119565791400_vdag218-B29","doi-asserted-by":"publisher","first-page":"W90","DOI":"10.1093\/nar\/gkw377","article-title":"Enrichr: a comprehensive gene set enrichment analysis web server 2016 update","volume":"44","author":"Kuleshov","year":"2016","journal-title":"Nucleic Acids Res"},{"key":"2026091119565791400_vdag218-B30","doi-asserted-by":"publisher","first-page":"e90","DOI":"10.1002\/cpz1.90","article-title":"Gene set knowledge discovery with Enrichr","volume":"1","author":"Xie","year":"2021","journal-title":"Curr Protoc"},{"key":"2026091119565791400_vdag218-B31","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1038\/s41586-021-03850-3","article-title":"A clinically applicable integrative molecular classification of meningiomas","volume":"597","author":"Nassiri","year":"2021","journal-title":"Nature"},{"key":"2026091119565791400_vdag218-B32","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","article-title":"The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data","volume":"2","author":"Cerami","year":"2012","journal-title":"Cancer Discov"},{"key":"2026091119565791400_vdag218-B33","doi-asserted-by":"publisher","first-page":"pl1","DOI":"10.1126\/scisignal.2004088","article-title":"Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal","volume":"6","author":"Gao","year":"2013","journal-title":"Sci Signal"},{"key":"2026091119565791400_vdag218-B34","doi-asserted-by":"publisher","first-page":"19550","DOI":"10.1038\/s41598-021-98911-y","article-title":"A vascularized tumoroid model for human glioblastoma angiogenesis","volume":"11","author":"Tatla","year":"2021","journal-title":"Sci Rep"},{"key":"2026091119565791400_vdag218-B35","doi-asserted-by":"publisher","first-page":"e27385","DOI":"10.1371\/journal.pone.0027385","article-title":"A computational tool for quantitative analysis of vascular networks","volume":"6","author":"Zudaire","year":"2011","journal-title":"PLoS One"},{"key":"2026091119565791400_vdag218-B36","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/s1535-6108(03)00187-9","article-title":"TSC2 regulates VEGF through mTOR-dependent and -independent pathways","volume":"4","author":"Brugarolas","year":"2003","journal-title":"Cancer Cell"},{"key":"2026091119565791400_vdag218-B37","doi-asserted-by":"publisher","first-page":"4643","DOI":"10.2147\/OTT.S205160","article-title":"Rapamycin suppresses angiogenesis and lymphangiogenesis in melanoma by downregulating VEGF-A\/VEGFR-2 and VEGF-C\/VEGFR-3 expression","volume":"12","author":"Wang","year":"2019","journal-title":"Onco Targets Ther"},{"key":"2026091119565791400_vdag218-B38","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1016\/j.ccell.2015.10.004","article-title":"Constitutive activation of mTORC1 in endothelial cells leads to the development and progression of lymphangiosarcoma through VEGF autocrine signaling","volume":"28","author":"Sun","year":"2015","journal-title":"Cancer Cell"},{"key":"2026091119565791400_vdag218-B39","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.ydbio.2007.03.004","article-title":"Paracrine and autocrine mechanisms of apelin signaling govern embryonic and tumor angiogenesis","volume":"305","author":"K\u00e4lin","year":"2007","journal-title":"Dev Biol"},{"key":"2026091119565791400_vdag218-B40","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.55589","article-title":"Apelin signaling drives vascular endothelial cells toward a pro-angiogenic state","volume":"9","author":"Helker","year":"2020","journal-title":"Elife"},{"key":"2026091119565791400_vdag218-B41","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1172\/JCI128469","article-title":"Apelin directs endothelial cell differentiation and vascular repair following immune-mediated injury","volume":"130","author":"Masoud","year":"2020","journal-title":"J Clin Invest"},{"key":"2026091119565791400_vdag218-B42","doi-asserted-by":"publisher","first-page":"e9266","DOI":"10.15252\/emmm.201809266","article-title":"Apelin inhibition prevents resistance and metastasis associated with anti-angiogenic therapy","volume":"11","author":"Uribesalgo","year":"2019","journal-title":"EMBO Mol Med"},{"key":"2026091119565791400_vdag218-B43","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1111\/cas.12836","article-title":"Apelin as a marker for monitoring the tumor vessel normalization window during antiangiogenic therapy","volume":"107","author":"Zhang","year":"2016","journal-title":"Cancer Sci"},{"key":"2026091119565791400_vdag218-B44","doi-asserted-by":"publisher","first-page":"2298","DOI":"10.1158\/0008-5472.CAN-18-0881","article-title":"Targeting APLN\/APLNR improves antiangiogenic efficiency and blunts proinvasive side effects of VEGFA\/VEGFR2 blockade in glioblastoma","volume":"79","author":"Mastrella","year":"2019","journal-title":"Cancer Res"},{"key":"2026091119565791400_vdag218-B45","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1097\/JTO.0b013e3181e2c1ff","article-title":"Apelin expression in human non-small cell lung cancer: role in angiogenesis and prognosis","volume":"5","author":"Berta","year":"2010","journal-title":"J Thorac Oncol"},{"key":"2026091119565791400_vdag218-B46","first-page":"5313","article-title":"The apelin-APJ system induces tumor arteriogenesis in hepatocellular carcinoma","volume":"34","author":"Muto","year":"2014","journal-title":"Anticancer Res"},{"key":"2026091119565791400_vdag218-B47","doi-asserted-by":"publisher","first-page":"3404","DOI":"10.1021\/acs.jmedchem.5c03424","article-title":"Design, synthesis, and pharmacological evaluation of metabolically stable apelin receptor antagonists with improved in vivo exposure and efficacy in ovarian cancer","volume":"69","author":"Elsheikh","year":"2026","journal-title":"J Med Chem"},{"key":"2026091119565791400_vdag218-B48","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1101\/gad.2042311","article-title":"mTOR phosphorylates IMP2 to promote IGF2 mRNA translation by internal ribosomal entry","volume":"25","author":"Dai","year":"2011","journal-title":"Genes Dev"},{"key":"2026091119565791400_vdag218-B49","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1002\/cbf.2824","article-title":"Rapamycin inhibits the invasive ability of thyroid cancer cells by down-regulating the expression of VEGF-C in vitro","volume":"30","author":"Feng","year":"2012","journal-title":"Cell Biochem Funct"}],"container-title":["Neuro-Oncology Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/noa\/advance-article-pdf\/doi\/10.1093\/noajnl\/vdag218\/70673507\/vdag218.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/noa\/article-pdf\/8\/1\/vdag218\/70673507\/vdag218.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/noa\/article-pdf\/8\/1\/vdag218\/70673507\/vdag218.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T23:57:02Z","timestamp":1789171022000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/noa\/article\/doi\/10.1093\/noajnl\/vdag218\/8762951"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1,12]]}},"URL":"https:\/\/doi.org\/10.1093\/noajnl\/vdag218","relation":{},"ISSN":["2632-2498"],"issn-type":[{"value":"2632-2498","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,1]]},"published":{"date-parts":[[2026,1]]},"article-number":"vdag218"}}